OpenNashEarnings

GE HealthCare (GEHC) · Medical Devices

GE HealthCare Q2 2026 earnings: summary, key numbers & outlook

Results filed 29 Jul 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

GE HealthCare's combined imaging segment and growing theranostics push drove orders across every segment, while Patient Care Solutions struggled and is now under strategic review.

GE HealthCare merged its Imaging and Advanced Visualization Solutions businesses into one segment, Advanced Imaging Solutions, leaving three reportable segments. Orders grew in every segment, which management tied to commercial execution and adoption of new products, with backlog at $23.9 billion. Pharmaceutical Diagnostics and Advanced Imaging Solutions led growth. Partnerships in theranostics (with Mayo Clinic and University Hospital Essen) and a health system deal on Long Island expanded the footprint. Patient Care Solutions kept shrinking.

Management is steering toward precision innovation, meaning AI-enabled imaging, nuclear medicine, theranostics and cloud software, while reviewing strategic options for Patient Care Solutions. The main tension is that the company is investing for growth while a weak segment drags on performance and costs rise for memory chips, oil and freight, roughly $250 million of inflation expected this year. Tariff refunds are not a lasting benefit.

No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.

Key numbers

Revenue · GAAP
$5.3 billion

up 5.7% from a year ago

Net income attributable to GE HealthCare · GAAP
$561 million

versus $486 million a year ago

Diluted EPS · GAAP
$1.24

grew 16.5%

Adjusted EPS · non-GAAP
$1.13

grew 6.6%

Adjusted EBIT margin · non-GAAP
14.2%

versus 14.6%, down 40 bps

Cash flow from operating activities · GAAP
$168 million

up $74 million

Free cash flow · non-GAAP
$68 million

up $61 million

Organic orders growth · non-GAAP
11.1%

versus 3.4% growth in the year-ago period

Segment or metricValueChange
Advanced Imaging Solutions revenue$3.8Bup 7.9%; organic up 5.0%
Pharmaceutical Diagnostics revenue$843.0Mup 15.6%; organic up 14.6%
Patient Care Solutions revenue$675.0Mdown 13.3%; organic down 13.5%
Backlog$23.9 billionbook-to-bill of 1.15 times
Where each number comes from
  • Revenue: “Revenues of $5.3 billion, up 5.7%, including Organic revenue growth* of 3.5%, driven by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS)”
  • Net income attributable to GE HealthCare: “Net income attributable to GE HealthCare of $561 million versus $486 million, and Adjusted EBIT* of $750 million versus $729 million”
  • Diluted EPS: “diluted earnings per share (EPS) of $1.24 grew 16.5% and Adjusted EPS* of $1.13 grew 6.6%”
  • Adjusted EPS: “diluted earnings per share (EPS) of $1.24 grew 16.5% and Adjusted EPS* of $1.13 grew 6.6%”
  • Adjusted EBIT margin: “Adjusted EBIT margin* of 14.2% versus 14.6%, down 40 bps, with both measures negatively impacted by a decline in PCS”
  • Cash flow from operating activities: “Cash flow from operating activities of $168 million, up $74 million. Free cash flow* of $68 million, up $61 million.”
  • Free cash flow: “Cash flow from operating activities of $168 million, up $74 million. Free cash flow* of $68 million, up $61 million.”
  • Organic orders growth: “Total orders up 11.1% organically versus 3.4% growth in the year-ago period, book-to-bill of 1.15 times and backlog of $23.9 billion.”
  • Advanced Imaging Solutions revenue: “Segment($ in millions) | Advanced Imaging Solutions | Pharmaceutical Diagnostics | Patient Care Solutions Segment Revenues | $3,771 | $843 | $675”
  • Pharmaceutical Diagnostics revenue: “Segment($ in millions) | Advanced Imaging Solutions | Pharmaceutical Diagnostics | Patient Care Solutions Segment Revenues | $3,771 | $843 | $675”
  • Patient Care Solutions revenue: “Segment($ in millions) | Advanced Imaging Solutions | Pharmaceutical Diagnostics | Patient Care Solutions Segment Revenues | $3,771 | $843 | $675”
  • Backlog: “Total orders up 11.1% organically versus 3.4% growth in the year-ago period, book-to-bill of 1.15 times and backlog of $23.9 billion.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$5.3B+5.8%+3.2%
Operating income$739.0M+13.0%+43.5%
Net income$561.0M+15.4%+44.2%
Diluted EPS$1.24+17.0%+45.9%
Free cash flow$68.0M+750.0%−39.3%
Gross margin41.2%+1.6 pts+2.7 pts
Operating margin14.0%+0.9 pts+4.0 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Organic revenue growthfull-year 20263.0% to 4.0%
Adjusted EBIT marginfull-year 202615.4% to 15.7%
Adjusted effective tax ratefull-year 202620.0% to 21.0%
Adjusted EPSfull-year 2026$4.80 to $5.00
Free cash flowfull-year 2026approximately $1.6 billion
Inflation from memory chips, oil, freight and other componentsfull-year 2026approximately $250 million

Key takeaways

  1. Orders grew in every segment, with record backlog

    Total orders rose 11.1% organically with book-to-bill of 1.15 times, leaving backlog at $23.9 billion. Management credited commercial execution and adoption of new products, which signals demand ahead of revenue.

  2. Patient Care Solutions is under strategic review

    The segment's organic revenue fell 13.5% and it posted a loss at the segment level. The CEO said the company is focused on returning it to growth and profitability while reviewing strategic options to maximize its long-term value.

  3. Two imaging businesses combined into Advanced Imaging Solutions

    Imaging and Advanced Visualization Solutions now report as one segment, leaving three reportable segments. The new segment produced the largest share of revenue, with 5.0% organic growth.

  4. Theranostics partnerships widen the personalized cancer care push

    GE HealthCare announced a research collaboration with Mayo Clinic and a new Nuclear Medicine Center with University Hospital Essen. These extend the Pharmaceutical Diagnostics and nuclear medicine strategy, with PDx organic revenue up 14.6%.

  5. AI and cloud software keep expanding the portfolio

    The company received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0 for radiation therapy planning and submitted MIM KineticID for 4D dynamic PET imaging. It also promoted cloud-enabled enterprise imaging, reflecting the stated focus on cloud, edge computing and AI.

Charts

Revenue$5.3B+5.8% y/yQ2 2026
Q4 2024: $5.3B (worked out from the annual figure)Q4 ’24$5.3BQ1 2025: $4.8BQ1 ’25$4.8BQ2 2025: $5.0BQ2 ’25$5.0BQ3 2025: $5.1BQ3 ’25$5.1BQ4 2025: $5.7B (worked out from the annual figure)Q4 ’25$5.7BQ1 2026: $5.1BQ1 ’26$5.1BQ2 2026: $5.3BQ2 ’26$5.3BQ3 2026: $5.5BQ3 ’26$5.5B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$5.3B *
Q1 2025$4.8B
Q2 2025$5.0B
Q3 2025$5.1B
Q4 2025$5.7B *
Q1 2026$5.1B
Q2 2026$5.3B
Q3 2026$5.5B
Diluted EPS (GAAP)$1.24+17.0% y/yQ2 2026
Q1 2025: $1.23Q1 ’25$1.23Q2 2025: $1.06Q2 ’25$1.06Q3 2025: $0.98Q3 ’25$0.98Q1 2026: $0.85Q1 ’26$0.85Q2 2026: $1.24Q2 ’26$1.24Q3 2026: $1.36Q3 ’26$1.36
Data
Q1 2025$1.23
Q2 2025$1.06
Q3 2025$0.98
Q1 2026$0.85
Q2 2026$1.24
Q3 2026$1.36

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin14.0%+0.9 pts y/yQ2 2026
Q4 2024: 15.1%Q4 ’2415.1%Q1 2025: 13.2%Q1 ’2513.2%Q2 2025: 13.1%Q2 ’2513.1%Q3 2025: 12.7%Q3 ’2512.7%Q4 2025: 14.5%Q4 ’2514.5%Q1 2026: 10.0%Q1 ’2610.0%Q2 2026: 14.0%Q2 ’2614.0%Q3 2026: 14.6%Q3 ’2614.6%
Data
Q4 202415.1%
Q1 202513.2%
Q2 202513.1%
Q3 202512.7%
Q4 202514.5%
Q1 202610.0%
Q2 202614.0%
Q3 202614.6%
Free cash flow$68.0M+750.0% y/yQ2 2026
Q1 2025: $98.0MQ1 ’25$98.0MQ2 2025: $8.0MQ2 ’25$8.0MQ3 2025: $483.0MQ3 ’25$483.0MQ1 2026: $112.0MQ1 ’26$112.0MQ2 2026: $68.0MQ2 ’26$68.0MQ3 2026: $793.0MQ3 ’26$793.0M
Data
Q1 2025$98.0M
Q2 2025$8.0M
Q3 2025$483.0M
Q1 2026$112.0M
Q2 2026$68.0M
Q3 2026$793.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What changed in GE HealthCare's reporting structure this quarter?

It combined Imaging and Advanced Visualization Solutions into a new segment, Advanced Imaging Solutions. The company now reports three segments: Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions, with history recast.

What is GE HealthCare doing about Patient Care Solutions?

The CEO said management is focused on returning the business to growth and profitability while reviewing strategic options to maximize its long-term value. The segment's organic revenue declined 13.5% this quarter.

How strong was customer demand in the quarter?

Organic orders grew 11.1%, versus 3.4% a year earlier, with growth in every segment. Book-to-bill was 1.15 times and backlog reached $23.9 billion.

Where is GE HealthCare investing in new products and partnerships?

It is investing in theranostics and nuclear medicine through collaborations with Mayo Clinic and University Hospital Essen, and in AI tools such as MIM Contour ProtégéAI+ 2.0 and MIM KineticID. It also highlighted cloud-enabled enterprise imaging and a partnership with Catholic Health on Long Island.

What cost pressures is management flagging?

Management continues to expect approximately $250 million of inflation tied to memory chips, oil, freight and other components this year. The company also said it does not expect a material further benefit from tariff refunds for 2026 tariffs, and it reaffirmed its full-year guidance.

Documents

SEC filing